X

logo

(-)-Epicatechin dosing in normal and overweight / obese subjects showed a 30% reduction in C-reactive protein, a key marker of inflammation in the body

Published November 2016
Cardiac muscle

This randomized, placebo-controlled, and double-blind study was conducted on 30 human subjects with high triglyceride levels for 4 weeks.

 

A precise formulation and dosage of (-)-epicatechin was administered to the treated group.

 

Note that the formulation and dosage of (-)-epicatechin used in this clinical are relevant to our key ingredient, Mitokatylst™ in the product Mitokatylst™ – E.

 

Blood samples were collected in all subjects to assess indicators of glucose and lipid control as well as inflammation.

Key Takeaways

  • A significant reduction of the levels of high-sensitivity C-reactive protein (hs-CRP) was noted (-30.2% in the treated group) while the placebo group did not show any change in their hs-CRP levels. The hs-CRP test is used to estimate inflammation in the body and can help predict the risk of heart disease and stroke.
  • Test results for the treated subjects showed significant decreases in triglycerides (-30%) versus the placebo group (-12.9%). The group receiving (-)-epicatechin also showed a 25.8% reduction in their TG/HDLc index whereas the placebo group showed a 5.7% reduction.
  • Test results also demonstrated significant decreases in fructosamine blood levels suggesting improved blood glucose control.
  • The effects of (-)-epicatechin appeared more prominent in the overweight subjects.

READ PAPER

Authors Gabriela Gutiérrez-Salmeán, Eduardo Meaney, Miguel A. Lanaspa, Christina Cicerchi, Richard J. Johnson, Sundeep Dugar, Pam Taub, Israel Ramírez-Sánchez, Francisco Villarreal, George Schreiner, Guillermo Ceballos